English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA Conference
Biogen Inc. announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies. These updates were presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 13-16, 2022).
First Patient Treated in Phase 3b ASCEND Study
The ASCEND study is currently enrolling with the first patient treated in Q1 2022. At the conference, Biogen presented the design of the open-label, global Phase 3b study to evaluate the potential benefit of investigational higher dose nusinersen in later-onset, non-ambulatory SMA patients previously treated with Evrysdi® (risdiplam).
“As the SMA community gains more experience with available therapies, we are gleaning new insights about how these treatments can enhance the lives of individuals impacted by SMA. However, unmet needs still remain for the community,” said Basil Darras, M.D., Professor of Neurology at Harvard Medical School and Director of the Neuromuscular Center and Spinal Muscular Atrophy Program at Boston Children’s Hospital. “The ASCEND study seeks to generate data that have the potential to inform decisions regarding treatment for our patients with later-onset SMA.”
BookmarkRelated Content
-
Will Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therap...In these days of the never-ending pandem...
-
Assessment of Cerebral Spinal Fluid Biomarkers and microRNA-Mediated Disease Mechanisms in Spinal Muscular Atrophy P...Cerebral spinal fluid (CSF) is a promisi...
-
Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database AnalysisSpinal muscular atrophy (SMA) is a rare,...
-
Safety and Efficacy of Once-Daily Risdiplam in Type 2 and Non-Ambulant Type 3 Spinal Muscular Atrophy (SUNFISH Part ...Background: Risdiplam is an oral small m...
-
Pharmacological and Clinical Profile of Onasemnogene Aveparvovec, the First Gene Therapy for Spinal Muscular Atrophy...Onasemnogene abeparvovec (Zolgensma; for...
-
John Hopkins – Spinal Muscular Atrophy (SMA) CenterThe Spinal Muscular Atrophy (SMA) Center...
-
SMA Gene Replacement Therapyhttps://www.youtube.com/watch?v=vHbJs8bm...
Powered by
In partnership with
